Evolus

Evolus reported Q2 2026 revenue of $84.1m (+21% y/y), beating analysts' estimates and raising the lower end of its full-year revenue guidance to $330m. Adjusted EBITDA was positive at $4.7m for the third consecutive quarter, although EPS of -$0.12 was more negative than expected. Management emphasized portfolio diversification through Evolysse and Profhilo and additional product launches; the stock rose about 5.7% in after-hours trading. » More on de.investing.com

Evolus has reached an exclusive license and distribution agreement with Swiss pharmaceutical company IBSA for the skin injection Profhilo in the US. Evolus will assume the development activities required for US approval and will market the product after approval; the agreement includes no upfront payments and is based on a transfer-pricing model. The company expects no impact from the agreement on its 2026 guidance or on the revenue and profitability targets for 2028. Profhilo, a superficially acting hyaluronic acid formulation to improve skin quality, has already been used in millions of treatments worldwide since 2015 and complements Evolus' existing portfolio such as Jeuveau and Evolysse. » More on de.investing.com

At Evolus' annual general meeting, Brady Stewart and Vikram Malik were reelected as Class II directors for three years. Shareholders confirmed Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and voted in a non-binding advisory vote to approve the compensation of the named executive officers. Additionally, the company reported mixed Q1 results (EPS missed, revenue slightly above expectations) and plans the European launch of the Estyme dermal filler line. » More on de.investing.com